vs
COMMERCE BANCSHARES INC（CBSH）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是COMMERCE BANCSHARES INC的1.6倍（$772.1M vs $475.7M），COMMERCE BANCSHARES INC净利率更高（29.8% vs 12.7%，领先17.0%），COMMERCE BANCSHARES INC同比增速更快（11.1% vs 5.9%），过去两年Revvity的营收复合增速更高（9.0% vs 7.1%）
Commerce Bancshares, Inc.是总部位于美国密苏里州的区域性银行控股公司，在堪萨斯城和圣路易斯设有核心办公点，旗下Commerce Bank提供多元化金融服务，覆盖企业及个人银行、财富管理、关联公司投资等业务。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CBSH vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.6倍
$475.7M
营收增速更快
CBSH
高出5.3%
5.9%
净利率更高
CBSH
高出17.0%
12.7%
两年增速更快
RVTY
近两年复合增速
7.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $475.7M | $772.1M |
| 净利润 | $141.6M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | — | 14.5% |
| 净利率 | 29.8% | 12.7% |
| 营收同比 | 11.1% | 5.9% |
| 净利润同比 | 10.5% | 3.9% |
| 每股收益（稀释后） | $0.96 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CBSHRVTY
| Q1 26 | $475.7M | — | ||
| Q4 25 | $449.4M | $772.1M | ||
| Q3 25 | $441.0M | $698.9M | ||
| Q2 25 | $445.8M | $720.3M | ||
| Q1 25 | $428.1M | $664.8M | ||
| Q4 24 | $422.1M | $729.4M | ||
| Q3 24 | $421.4M | $684.0M | ||
| Q2 24 | $414.5M | $691.7M |
净利润CBSHRVTY
| Q1 26 | $141.6M | — | ||
| Q4 25 | $140.7M | $98.4M | ||
| Q3 25 | $141.5M | $46.7M | ||
| Q2 25 | $152.5M | $53.9M | ||
| Q1 25 | $131.6M | $42.2M | ||
| Q4 24 | $136.1M | $94.6M | ||
| Q3 24 | $138.0M | $94.4M | ||
| Q2 24 | $139.6M | $55.4M |
毛利率CBSHRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率CBSHRVTY
| Q1 26 | — | — | ||
| Q4 25 | 40.8% | 14.5% | ||
| Q3 25 | 41.9% | 11.7% | ||
| Q2 25 | 44.0% | 12.6% | ||
| Q1 25 | 39.2% | 10.9% | ||
| Q4 24 | 41.2% | 16.3% | ||
| Q3 24 | 42.4% | 14.3% | ||
| Q2 24 | 43.4% | 12.4% |
净利率CBSHRVTY
| Q1 26 | 29.8% | — | ||
| Q4 25 | 31.3% | 12.7% | ||
| Q3 25 | 32.1% | 6.7% | ||
| Q2 25 | 34.2% | 7.5% | ||
| Q1 25 | 30.7% | 6.4% | ||
| Q4 24 | 32.2% | 13.0% | ||
| Q3 24 | 32.8% | 13.8% | ||
| Q2 24 | 33.7% | 8.0% |
每股收益（稀释后）CBSHRVTY
| Q1 26 | $0.96 | — | ||
| Q4 25 | $0.86 | $0.86 | ||
| Q3 25 | $1.06 | $0.40 | ||
| Q2 25 | $1.14 | $0.46 | ||
| Q1 25 | $0.98 | $0.35 | ||
| Q4 24 | $0.83 | $0.77 | ||
| Q3 24 | $1.01 | $0.77 | ||
| Q2 24 | $1.03 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.3B | $7.3B |
| 总资产 | $35.7B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CBSHRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B |
股东权益CBSHRVTY
| Q1 26 | $4.3B | — | ||
| Q4 25 | $3.8B | $7.3B | ||
| Q3 25 | $3.8B | $7.4B | ||
| Q2 25 | $3.6B | $7.6B | ||
| Q1 25 | $3.5B | $7.6B | ||
| Q4 24 | $3.3B | $7.7B | ||
| Q3 24 | $3.4B | $7.9B | ||
| Q2 24 | $3.1B | $7.9B |
总资产CBSHRVTY
| Q1 26 | $35.7B | — | ||
| Q4 25 | $32.9B | $12.2B | ||
| Q3 25 | $32.3B | $12.1B | ||
| Q2 25 | $32.3B | $12.4B | ||
| Q1 25 | $32.4B | $12.4B | ||
| Q4 24 | $32.0B | $12.4B | ||
| Q3 24 | $31.5B | $12.8B | ||
| Q2 24 | $30.6B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流CBSHRVTY
| Q1 26 | — | — | ||
| Q4 25 | $645.1M | $182.0M | ||
| Q3 25 | $129.0M | $138.5M | ||
| Q2 25 | $111.2M | $134.3M | ||
| Q1 25 | $138.6M | $128.2M | ||
| Q4 24 | $577.9M | $174.2M | ||
| Q3 24 | $431.7M | $147.9M | ||
| Q2 24 | $147.4M | $158.6M |
自由现金流CBSHRVTY
| Q1 26 | — | — | ||
| Q4 25 | $592.4M | $161.8M | ||
| Q3 25 | $113.3M | $120.0M | ||
| Q2 25 | $100.5M | $115.5M | ||
| Q1 25 | $126.0M | $112.2M | ||
| Q4 24 | $531.7M | $149.8M | ||
| Q3 24 | $419.1M | $125.6M | ||
| Q2 24 | $138.9M | $136.6M |
自由现金流率CBSHRVTY
| Q1 26 | — | — | ||
| Q4 25 | 131.8% | 21.0% | ||
| Q3 25 | 25.7% | 17.2% | ||
| Q2 25 | 22.5% | 16.0% | ||
| Q1 25 | 29.4% | 16.9% | ||
| Q4 24 | 126.0% | 20.5% | ||
| Q3 24 | 99.5% | 18.4% | ||
| Q2 24 | 33.5% | 19.7% |
资本支出强度CBSHRVTY
| Q1 26 | — | — | ||
| Q4 25 | 11.7% | 2.6% | ||
| Q3 25 | 3.6% | 2.6% | ||
| Q2 25 | 2.4% | 2.6% | ||
| Q1 25 | 2.9% | 2.4% | ||
| Q4 24 | 10.9% | 3.4% | ||
| Q3 24 | 3.0% | 3.3% | ||
| Q2 24 | 2.1% | 3.2% |
现金转化率CBSHRVTY
| Q1 26 | — | — | ||
| Q4 25 | 4.59× | 1.85× | ||
| Q3 25 | 0.91× | 2.97× | ||
| Q2 25 | 0.73× | 2.49× | ||
| Q1 25 | 1.05× | 3.03× | ||
| Q4 24 | 4.25× | 1.84× | ||
| Q3 24 | 3.13× | 1.57× | ||
| Q2 24 | 1.06× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CBSH
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
